Your browser doesn't support javascript.
loading
Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
Al-Sawaf, Othman; Zhang, Can; Jin, Hyun Yong; Robrecht, Sandra; Choi, Yoonha; Balasubramanian, Sandhya; Kotak, Alex; Chang, Yi Meng; Fink, Anna Maria; Tausch, Eugen; Schneider, Christof; Ritgen, Matthias; Kreuzer, Karl-Anton; Chyla, Brenda; Paulson, Joseph N; Pallasch, Christian P; Frenzel, Lukas P; Peifer, Martin; Eichhorst, Barbara; Stilgenbauer, Stephan; Jiang, Yanwen; Hallek, Michael; Fischer, Kirsten.
Afiliação
  • Al-Sawaf O; Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany. othman.al-sawaf@uk-koeln.de.
  • Zhang C; Cancer Institute, University College London, London, UK. othman.al-sawaf@uk-koeln.de.
  • Jin HY; Francis Crick Institute, London, UK. othman.al-sawaf@uk-koeln.de.
  • Robrecht S; Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
  • Choi Y; Genentech Inc., South San Francisco, CA, USA.
  • Balasubramanian S; Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
  • Kotak A; Genentech Inc., South San Francisco, CA, USA.
  • Chang YM; Genentech Inc., South San Francisco, CA, USA.
  • Fink AM; Roche Products Ltd, Welwyn Garden City, UK.
  • Tausch E; Hoffmann-la Roche, Mississauga, ON, Canada.
  • Schneider C; Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
  • Ritgen M; Department III of Internal Medicine, Ulm University, Ulm, Germany.
  • Kreuzer KA; Department III of Internal Medicine, Ulm University, Ulm, Germany.
  • Chyla B; Department II of Internal Medicine, University of Schleswig Holstein, Kiel, Germany.
  • Paulson JN; Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
  • Pallasch CP; AbbVie Inc., North Chicago, IL, USA.
  • Frenzel LP; Genentech Inc., South San Francisco, CA, USA.
  • Peifer M; Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
  • Eichhorst B; Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
  • Stilgenbauer S; Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, University of Cologne, Cologne, Germany.
  • Jiang Y; Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
  • Hallek M; Department III of Internal Medicine, Ulm University, Ulm, Germany.
  • Fischer K; Genentech Inc., South San Francisco, CA, USA.
Nat Commun ; 14(1): 6724, 2023 Oct 23.
Article em En | MEDLINE | ID: mdl-37872229
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article